Description

Moxin (moxifloxacin) Coated Tablets 400 mg. №5

Ingredients

Active ingredient: Moxifloxacin 400 mg.
Other ingredients: Microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol.

Dosage

Recommended dosage: 1 tablet daily, or as directed by a healthcare professional.
Do not exceed the recommended dose.

Indications

Moxin tablets are indicated for the treatment of bacterial infections such as respiratory tract infections, skin and soft tissue infections, and urinary tract infections caused by susceptible strains of bacteria.

Contraindications

Do not use Moxin tablets if you have a history of hypersensitivity to moxifloxacin or any other fluoroquinolones.

Directions

Take Moxin tablets orally with a full glass of water, with or without food, as directed by your healthcare provider.

Scientific Evidence

Moxifloxacin, the active ingredient in Moxin tablets, is a broad-spectrum antibiotic that works by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes, thereby disrupting DNA replication and transcription. Clinical studies have shown the efficacy of moxifloxacin in treating various bacterial infections, with a good safety profile.

Additional Information

It is important to complete the full course of treatment with Moxin tablets as prescribed by your doctor, even if you start to feel better before the course is finished.
Consult your healthcare provider if you experience any severe side effects such as tendon rupture, allergic reactions, or persistent diarrhea.

Pharmacological Effects: Moxifloxacin exhibits its antibacterial activity by interfering with the enzymes necessary for bacterial DNA replication. This mechanism of action leads to the inhibition of bacterial growth and eventual eradication of the infection.

Clinical Trials: Clinical trials have demonstrated the effectiveness of moxifloxacin in treating respiratory tract infections, skin infections, and urinary tract infections. One study published in the Journal of Antimicrobial Chemotherapy showed that moxifloxacin had a high success rate in treating community-acquired pneumonia.